Dr. Spigelman received his M.Sc and PhD from the University of British Columbia, and is a Professor in the UCLA School of Dentistry. He is a neuropharmacologist conducting translational neurobiology research into disorders such as chronic pain, addiction, and epilepsy. His work has studies the distribution of cannabinoid receptors and their endogenous ligands in chronic pain and alcohol dependence. He has developed novel synthetic cannabinoids that don’t have psychotropic effects. These novel cannabinoids have the potential to benefit the hundreds of millions patients suffering from chronic pain while reducing reliance on opioids and other drugs with addictive potential and central nervous system side effects.